# A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

> **NCT04521231** · PHASE1,PHASE2 · RECRUITING · sponsor: **Amgen** · enrollment: 281 (estimated)

## Conditions studied

- B Cell Precursor Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT04521231
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-04
- **Primary completion:** 2027-11-24
- **Final completion:** 2029-05-25
- **Target enrollment:** 281 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521231, "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04521231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*